Product Program year 2024 Source: CMS Open Payments

AirDuo Digihaler

Drug Respiratory

NDC 59310-111-06

Open in the dashboard

General payments

$542,064

22,131 payments

Research payments

$459,477

15 payments

Through program year 2024, $542,064 in general payments and $459,477 in research payments were reported against AirDuo Digihaler (Respiratory).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

8 rows
Year Kind Amount Payments
2024 General $2,997 7
2024 Research $64,483 5
2023 General $40,870 1,032
2022 General $135,005 7,517
2022 Research $1,960 2
2021 General $208,567 12,603
2021 Research $393,035 8
2020 General $154,625 972

Breakdown

Who paid General payments · program years 2020–2024
  1. Teva Pharmaceuticals USA, Inc. $542,064 22,131 payments
Top recipients General payments · program year 2024
  1. Maeve Oconnor Allergy & Immunology · Charlotte, NC $428 14% · 1 payment
  2. Rajan Merchant Allergy & Immunology · Woodland, CA $428 14% · 1 payment
  3. Mario Castro Pulmonary Disease · Kansas City, KS $428 14% · 1 payment
  4. John Oppenheimer Allergy · Cedar Knolls, NJ $428 14% · 1 payment
  5. Njira Lugogo Pulmonary Disease · Ann Arbor, MI $428 14% · 1 payment

The top 5 of 7 recipients; each share is of general payments naming this product in 2024.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2024
  1. Pulmonary Disease Internal Medicine $856 33% · 2 practitioners
  2. Allergy & Immunology $856 33% · 2 practitioners
  3. Allergy Allergy & Immunology $428 17% · 1 practitioner
  4. Pediatric Allergy/Immunology Pediatrics $428 17% · 1 practitioner

Each share is of general payments naming this product to practitioners with a specialty in 2024. Each practitioner is counted under their primary specialty.

Where the money went General payments · program year 2024
  1. California $856 29% · 2 recipients
  2. Kansas $428 14% · 1 recipient
  3. Michigan $428 14% · 1 recipient
  4. Missouri $428 14% · 1 recipient
  5. New Jersey $428 14% · 1 recipient

The top 5 of 6 states; each share is of general payments naming this product in 2024 where a state was reported.

The top 25 states, free in the app

22,131 general · 15 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2024

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record